Table 2.
Relationship Between USP53 Expression, the Response to Radiotherapy, and Clinicopathological Parameters.
| Characteristics | Patients (n = 40) | USP53 expression positive (n = 10) | USP53 expression negative (n = 30) | P a |
|---|---|---|---|---|
| Age (years) | ||||
| ≦50 | 22 | 6 | 16 | |
| 50 | 18 | 4 | 14 | .503 |
| Tumor diameter | ||||
| <4 | 9 | 3 | 6 | |
| ≧4 | 31 | 7 | 24 | .399 |
| FIGO stage | ||||
| II | 37 | 9 | 28 | |
| III + IV | 3 | 1 | 2 | .589 |
| Tumor shape | ||||
| Endogenous type | 13 | 9 | 4 | |
| Exogenous type | 27 | 21 | 6 | .414 |
| Radiation sensitivity | ||||
| NV | 4 | 3 | 1 | |
| PR | 32 | 7 | 25 | |
| CR | 4 | 0 | 4 | .048 |
Abbreviations: CR, complete response; FIGO, Federation International of Gynecology and Obstetrics; PR, partial response; USP53, ubiquitin-specific protein 53.
a P value was estimated by Fisher exact test.